Skip to Content
  • Previous Rank
    28
  • Revenue 3 Yr Annual Growth Rate
    25%
  • Revenue 3 Yr Growth Rank
    61
  • EPS 3 Yr Annual Growth Rate
    65%
  • EPS 3 Yr Growth Rank
    25
  • Total Return 3 Yr Annual Rate
    23%
  • Total Return 3 Yr Rank
    54

Growth in its DNA: The world’s largest genetic sequencing company is launching a startup, Grail, to develop blood-based screenings for early cancer detection.

Company Information

Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.
Location
San Diego, Calif.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak2
Years on List4
CEO
Francis deSouza
Websitehttp://www.illumina.com

Revenue, Net Income

Revenue Past Four Quarters ($M)$2,253
Net Income Past Four Quarters ($M)$414

Growth Rates and Ranks

Revenue 3 Yr Growth Rank61
EPS 3 Yr Annual Growth Rate65%
EPS 3 Yr Growth Rank25
Total Return 3 Yr Annual Rate23%
Total Return 3 Yr Rank
54